3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
13
Neoplasms
11
Neoplasm Metastasis
11
Rectal Neoplasms
6
Lymphoma, Non-Hodgkin
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Fallopian Tube Neoplasms
4
Colorectal Cancer Metastatic
4
Colonic Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Burkitt Lymphoma
4
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Penile Neoplasms
2
Interventions
Oxaliplatin
14
Fluorouracil
11
Capecitabine
9
Surveys and Questionnaires
8
Leucovorin
8
Irinotecan
8
Cisplatin
8
Bevacizumab
8
Standard of Care
5
Gemcitabine
5
Drug Therapy
4
S 1 (combination)
3
Radiotherapy
3
Nivolumab
3
Interviews as Topic
3
IFL protocol
3
Educational Status
3
Cyclophosphamide
3
Colonoscopy
3
Blood Specimen Collection
3
5,10-methylenetetrahydrofolic acid
3
trebananib
2
tivozanib
2
pembrolizumab
2
Taxes
2
Remote Patient Monitoring
2
Pemetrexed
2
Panitumumab
2
Ocoxin
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gastrointestinal Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled